Skip to Main Content
research
nutrition
Cancer
Reporting from the frontiers of health and medicine
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
D.C. Diagnosis
STAT+

CDC and social media: The new misinformation war

  • Sarah Owermohle

By Sarah Owermohle Feb. 6, 2024

Reprints
Social media apps
KIRILL KUDRYAVTSEV/AFP/Getty Images

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.

In the age of misinformation, what can the government really do?

advertisement

The Supreme Court is set to hear arguments next month in a case that could have sweeping ramifications for federal health agencies’ efforts to combat misinformation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

About the Author Reprints

Sarah Owermohle

Sarah Owermohle

Washington Correspondent

Sarah Owermohle reports on the administration’s health care initiatives, federal health policy, and its intersection with politics and the courts. She joined STAT in 2022 after covering health policy at Politico. She is also the co-author of the free, twice-weekly D.C. Diagnosis newsletter.

Tags

STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.

A study says intermittent fasting is making people drop…
A study says intermittent fasting is making people drop dead. Oh, come on
No one — M.D. or otherwise — should use…
No one — M.D. or otherwise — should use the honorific ‘doctor’ with patients
Human reproductive cloning: The curious incident of the dog…
Human reproductive cloning: The curious incident of the dog in the night-time
Top U.S. addiction researcher calls GLP-1 data for addiction…
Top U.S. addiction researcher calls GLP-1 data for addiction ‘very, very exciting’
BioNTech is having its Pfizer moment
BioNTech is having its Pfizer moment
Pharma companies and their allies seek to exempt orphan…
Pharma companies and their allies seek to exempt orphan drugs from state pricing limits

Recommended Stories